# Johann S. de Bono

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/johann-s-de-bono/

## Facts

| Field | Value |
| --- | --- |
| Citations | 138,085 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 162 |
| i10-index | 799 |
| Last Known Institution | Royal Marsden NHS Foundation Trust |
| OpenAlex ID | https://openalex.org/A5072378199 |
| ORCID iD | 0000-0002-2034-595X |
| Works | 2,470 |

## Researcher papers

Showing 12 of 26.

- [Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy](https://scholariq.org/papers/increased-survival-with-enzalutamide-in-prostate-cancer-after-chemotherapy/)
- [Abiraterone and Increased Survival in Metastatic Prostate Cancer](https://scholariq.org/papers/abiraterone-and-increased-survival-in-metastatic-prostate-cancer/)
- [Integrative Clinical Genomics of Advanced Prostate Cancer](https://scholariq.org/papers/integrative-clinical-genomics-of-advanced-prostate-cancer/)
- [Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers](https://scholariq.org/papers/inhibition-of-poly-adp-ribose-polymerase-in-tumors-from-i-brca-i-mutation/)
- [Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial](https://scholariq.org/papers/prednisone-plus-cabazitaxel-or-mitoxantrone-for-metastatic-castration-resistant/)
- [Enzalutamide in Metastatic Prostate Cancer before Chemotherapy](https://scholariq.org/papers/enzalutamide-in-metastatic-prostate-cancer-before-chemotherapy/)
- [Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy](https://scholariq.org/papers/abiraterone-in-metastatic-prostate-cancer-without-previous-chemotherapy/)
- [Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/lutetium-177-psma-617-for-metastatic-castration-resistant-prostate-cancer/)
- [Olaparib for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/olaparib-for-metastatic-castration-resistant-prostate-cancer/)
- [DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer](https://scholariq.org/papers/dna-repair-defects-and-olaparib-in-metastatic-prostate-cancer/)
- [Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial](https://scholariq.org/papers/addition-of-docetaxel-zoledronic-acid-or-both-to-first-line-long-term-hormone/)
- [Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy](https://scholariq.org/papers/abiraterone-for-prostate-cancer-not-previously-treated-with-hormone-therapy/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)

## Researcher university

- [Royal Marsden NHS Foundation Trust](https://scholariq.org/institutions/royal-marsden-nhs-foundation-trust/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.